In this study, we examine the effects of tissue inhibitor of metalloproteinases-2 (TIMP-2) on the phosphorylation status of specific phosphotyrosine residues on the vascular endothelial cell growth factor receptor-2 (VEGFR-2) cytoplasmic tail and examine the effects on associated downstream signaling pathways. To focus on metalloproteinase-independent mechanisms, we used the TIMP-2 analog known as Ala þ TIMP-2 that is deficient in matrix metalloproteinase-inhibitory activity. Our experiments are designed to compare the effects of VEGF-A stimulation with or without Ala þ TIMP-2 pretreatment, as well as basal responses in human microvascular endothelial cells. Our results show that Ala þ TIMP-2 selectively alters the phosphorylation pattern of VEGFR-2 after VEGF-A stimulation and disrupts the downstream activation of PLC-g, Ca þ 2 flux, Akt, and eNOS, as well as decreasing cGMP levels. Moreover, we observed an Ala þ TIMP-2induced reduction in cGMP levels typically elevated by exogenous NO donors implicating Ala þ TIMP-2 in the direct activation of an isobutylmethylxanthine (IBMX)-sensitive cGMP phosphodiesterase activity. TIMP-2 suppression of endothelial mitogenesis and angiogenesis involves at least two mechanisms, one mediated by protein tyrosine phosphatase inhibition of VEGFR-2 activation as well as downstream signaling and a second mechanism involving direct activation of an IBMX-sensitive phosphodiesterase activity.
Tumor angiogenesis is initiated by the hypoxic conditions related to rapid tumor growth that initiates tumor cell transcriptional activation of vascular endothelial growth factor (VEGF)-A. 1 Tumor progression is also associated with remodeling of the extracellular matrix by members of the matrix metalloproteinase (MMP) family and concomitant release of proteolytic cleavage products of laminin, fibronectin, and collagens, as well as sequestered growth factors including VEGF-A. 2, 3 VEGF-A is well characterized as a potent inducer of endothelial cell proliferation, migration, and survival associated with tumor progression.
Vascular endothelial growth factor receptor-2 (VEGFR-2) signaling is critical for the angiogenic response associated with cancer progression. The central role of the VEGF-A/VEGFR-2 receptor axis in pathologic angiogenesis is reflected in the development of multiple Federal Drug Administration approved human therapeutic strategies that selectively target VEGF-A/ VEGFR-2. For example, Bevacisumab and Sunitinib are approved for cancer treatment, as well as Pegaptanib and Ranibizumad for treatment of patients with macular degeneration, and several other drugs are now in late stage clinical trials. [4] [5] [6] Similar to other receptor tyrosine kinases (RTKs) activation of VEGFR-2 signaling begins with ligand binding that results in receptor dimerization and autophosphorylation of specific tyrosine residues. 2, 7 Phosphorylation of specific tyrosine residues is essential for the recruitment and activation of Src-homolgy-2 (SH2) binding proteins that propagate downstream intracellular signaling pathways. VEGFR-2 initiated signaling pathways regulate endothelial cell proliferation, migration, survival and vascular permeability.
Mammalian tissue inhibitor of metalloproteinases (TIMPs) are a family of four relatively small proteins that contain six disulfide bonds. 8 TIMP-2 is unique in that, it is the only member of the family that functions to both inhibit MMP activity, and facilitate the cell surface activation of pro-MMP-2 through formation of a tri-molecular complex with MT1-MMP. 8 In addition, TIMP-2 is the only TIMP family member that is a potent inhibitor of human microvascular endothelial cell (hMVEC) mitogenesis in vitro and angiogenesis in vivo, and these effects are independent of MMPinhibitory activity, as shown by the TIMP-2 analog, Ala þ TIMP-2 that is devoid of MMP-inhibitory activity. [9] [10] [11] [12] The anti-angiogenic effect of TIMP-2 and Ala þ TIMP-2 involves heterologous receptor inactivation. The specific mechanism involves binding of TIMP-2 or Ala þ TIMP-2 to the a3b1 integrin, induction of protein tyrosine phosphatase (PTP) activity, and subsequent reduction in activation/ phosphorylation of angiogenic RTKs, such as VEGFR-2 and FGFR-1. [10] [11] [12] Furthermore, studies using mice 80-90% deficient in Shp-1 show that the in vivo anti-angiogenic activity of Ala þ TIMP-2 is dependent on Shp-1 activity. 13 In addition to inhibition of endothelial cell mitogenesis TIMP-2 inhibits endothelial cell migration, also via an Shp-1-dependent mechanism. 14 On the basis of our previous demonstration that all TIMP-2 and Ala þ TIMP-2 effects are Shp-1 dependent, we have not repeated these experiments here but choose to further our understanding of the anti-angiogenic mechanism of TIMP-2 through examining the effects on the pattern of VEGFR-2 phosphorylation in the cytoplasmic tail. To focus on MMP-independent effects of TIMP-2 experiments were conducted using the TIMP-2 analog, which we refer to as Ala þ TIMP-2 that is deficient in MMP-inhibitory activity. 15 We show for the first time that Ala þ TIMP-2 selectively alters VEGFR-2 phosphorylation, and diminished VEGF-Amediated activation of downstream effectors. Also for the first time, we observed that elevation of cGMP levels by administration of exogenous NO donors was directly downregulated by Ala þ TIMP-2 through induction of isobutylmethylxanthine (IBMX)-sensitive phosphodiesterase activity. These findings extend previous observations of the inhibitory effects of extracellular matrix proteins, specifically TIMP-2, on the proliferation and migration of hMVECs and provide novel insight into extracellular matrix regulatory signals that modulate cellular responses to VEGF-A.
MATERIALS AND METHODS Cell Lines, Growth Factors, Antibodies, and Reagents
Primary hMVECs and growth factors were purchased from commercial sources. Primary hMVECs were used between passages 3 and 6 for all experiments as described earlier. 11 Antibodies recognizing VEGFR-2 phosphorylated tyrosine residues: pY 951 , pY 1059 , and pY 1214 were purchased from Biosource (Invitrogen, Carlsbad, CA, USA); anti-pY 996 and anti-pY 1175 were from Cell Signaling Technology (Danvers, MA, USA). Anti-PLC-g-pY 783 and anti-PLC-g antibodies were from Biosource. Anti-phosho-AKT (S 473 ), anti-AKT, anti-phospho-eNOS (S 1177 ), and anti-eNOS antibodies were purchased from Cell Signaling Technology. Anti-VEGFR-2 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Diethyltriamine NONOate (DETA/NO) and fura2acetoxymethyl ester (fura-2, AM) were purchased from Cayman Chemical (Ann Arbor, MI, USA), and Molecular Probes (Invitrogen, Carlsbad, CA, USA), respectively. BAPTA-AM and 1H-(1,2,4) oxadiazole(4,3-a)quinoxalin-1one (ODQ) were obtained from BIOMOL (Plymouth Meeting, PA, USA). Sodium orthovanadate, okadaic acid, 8-Bromo (8Br)-cGMP, 4,5-diaminofluorescein diacetate (DAF-2DA), N o -nitro-L-arginine methyl ester (L-NAME), and 3-isobutyl-1-metylxanthine (IBMX) were purchased from Sigma-Aldrich Chemical (St Louis, MO, USA). Recombinant TIMP-2 and Ala þ TIMP-2 were prepared as described, and endotoxin tested using the Limulus amoebocyte lysis assay (o2 EU/mg protein), as reported earlier. 15 Cytosolic Ca 2 þ Measurement Increases in intracellular Ca 2 þ were measured using the Ca 2 þ -sensitive fluorescent dye fura-2 AM using gelatincoated 96-well black wall plates (BioCoat, BD Biosciences, San Jose, CA, USA). hMVECs were incubated with 4 mM fura-2 AM for 30 min at 371C, gently washed twice with Hank's balanced salt solution (Invitrogen), and treated as indicated. The treated cells were then imaged using a BD Pathway 855 bioimager (BD Biosciences). Regions of interest in individual cells were gated and excited at 334 and 380 nM with emission at 520 nM. The 334/380-excitation ratio, which increases as a function of intracellular Ca 2 þ concentration, was captured at 4-s intervals.
Immunoblotting and Immunoprecipitation
After specified treatments, hMVECs were rinsed twice with ice-cold phosphate-buffered saline and lysed in buffer A (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% sodium deoxycholate, and 1% Triton X-100), supplemented with 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mg/ml pepstatin, and 100 mM Na 3 VO 4 , for 20 min on ice. Insoluble material was removed by centrifugation at 41C for 20 min at 14 000 r.p.m. Protein concentration in the lysates was determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). To extract total eNOS protein, cells were lysed in buffer B containing SDS rather than Triton X-100 (50 mM Tris-HCl, pH 7.4, 2% SDS, 25 mM b-glycerophosphate, 50 mM NaF, and 0.5 mM Na 3 VO 4 ). hMVECs lysates were subjected to immunoprecipitation and western blot analysis as described earlier. 16 Chemiluminescent generated band intensities were integrated for quantification by the use of National Institutes of Health (NIH) Image J 1.34s software.
Nitric Oxide Measurements
Total NO was assayed using nitrate/nitrite fluorometric assay kit from Cayman Chemical. hMVECs were washed with phenol-free basal media and incubated with TIMP-2 (50 nM), Ala þ TIMP-2 (50 nM), or L-NAME (1 mM) in the absence of and presence of VEGF-A. The nitrite and nitrate released into the media were measured fluorimetrically (excitation wavelength 355 nM: emission wavelength 460 nM), according to the manufacturer's instructions (Cayman Chemical).
Intracellular NO was measured using the NO-specific fluorescence probe DAF-2DA as described. 17 Total fluorescence of the treated and washed samples was determined (emission wavelength, 485 nM; excitation wavelength 538 nM) using the bottom-reading mode in a fluorescence plate reader (Tecan).
Intracellular cGMP Measurement
Intracellular cGMP concentrations were determined as described earlier. 18 The experimental readings from each triplicate lysates falling within the linear region of the standard curve were evaluated with the Direct cGMP Assay Kit from Assay Designs (Ann Arbor, MI, USA).
Cell Proliferation Assay
The number of hMVECs, after indicated in vitro treatments, were determined using Cell-Titer 96 Aqueous One Solution reagent (Promega) according to the manufacturer's direction, as described earlier. 11 
Cell Migration Assay
To assess cell migration, the 'scratch' wound assay was performed as described earlier and quantified by measuring the width of the cell-free zone immediately before and 16 h after cell treatment using a computer-assisted microscope (Zeiss) at three distinct positions for each assay condition. The results are reported as the mean ± s.d. of these triplicate measurements.
Statistical Analysis
All data were analyzed using the Prism Statistical Software package (Software MacKiev, Graphpad Software, La Jolla, CA, USA) to perform two-sided student t-test of statistical significance or ANOVA analysis.
RESULTS

TIMP-2 Shows Selective Inhibition of VEGFR-2 Tyrosine Phosphorylation
We have reported earlier that treatment of hMVECs with TIMP-2 results in a significant decrease in total VEGFR-2 tyrosine phosphorylation after VEGF-A stimulation, 11 resulting in complete inhibition of VEGF-A-stimulated mitogenesis. This effect is independent of the ability of TIMP-2 to inhibit MMP activity, as shown by the use of a TIMP-2 derivative devoid of MMP-inhibitory activity, Ala þ TIMP-2. Furthermore, this effect was completely abrogated by the co-administration of the PTP-inhibitor sodium orthovanadate or genetic manipulation to reduce active Shp-1 levels. 11, 12 To further elucidate the mechanisms through which TIMP-2 downregulates VEGF-A-mediated pro-angiogenic signaling, we examined the phosphorylation status of several tyrosine residues after treatment of hMVECs at 0, 2, 5, and 10 min after VEGF-A stimulation with or without previous Ala þ TIMP-2 treatment, Figure 1 . It is well recognized that VEGFR-2 phosphorylation is maximal between 2-5 min after VEGF-A stimulation and decreases thereafter. 19 Of the five tyrosine residues examined (Y 951 , Y 996 , Y 1059 , Y 1175 , and Y 1214 ) VEGF-A treatment alone showed enhanced phosphorylation of these residues that peaked at 5 min. Pretreatment of the hMVECs with 50 nM Ala þ TIMP-2 for 30 min before VEGF-A stimulation resulted in minimal enhancement of Y 1059 and Y 1214 phosphorylation. These findings suggest that these residues are not targeted by the enhanced Shp-1 phosphatase activity previously observed after Ala þ TIMP-2 pretreatment of VEGF-A-stimulated hMVECs. 11, 12 In contrast, Ala þ TIMP-2 selectively suppressed maximal VEGF-A-stimulated phosphorylation of Y 951 , Y 996 , and Y 1175 of the VEGFR-2 cytoplasmic domain and this effect peaked at 5 min after stimulation, Figure 1 . These tyrosine residues have been specifically implicated in the regulation of hMVEC proliferation and migration, through initiation of critical downstream signaling pathways. Ala þ TIMP-2 decreased phosphorylation of these specific tyrosine residues ranged from B40% reduction for Y 951 to B50% reduction for both Y 996 and Y 1175 .
Zymogram analysis of MMP-2 expression revealed that Ala þ TIMP-2 or TIMP-2 (50 or 100 nM final concentration) treatment of hMVECs failed to alter expression or activation of this MMP (data not shown).
TIMP-2 Inhibits PLC-c Activation and Ca þ 2 Flux
As phosphorylation of Y 951 and Y 1175 are known to mediate activation of PLC-g, we postulated that Ala þ TIMP-2 reduction of phosphorylation at VEGFR-2 tyrosine residues Y 951 and Y 1175 , would decrease both PLC-g activation and cytosolic Ca þ 2 concentrations. As shown in Figure 2a , hMVECs treated with 50 nM Ala þ TIMP-2 before VEGF-A stimulation showed a significant (465%) decrease in the association of PLC-g with the VEGFR-2 at 5 min, as determined by immunoprecipitation analysis. We then examined the phosphorylation of PLC-g on Y 783 that has been associated with PLC-g activation in vitro and in vivo. 20 At 2 min after treatment with VEGF-A, PLC-g showed a B9.0-fold increase in Y 783 phosphorylation that was not significantly attenuated by TIMP-2 pretreatment, Figure 2b . However, at 5 min post-treatment PLC-g activation as determined by Y 783 phosphorylation was decreased by 40%. This observation suggest that Ala þ TIMP-2 may not suppress maximal phosphorylation of PLC-g at 2 min after VEGF-A stimulation, but does accelerate dephosphorylation as shown by reduced phosphorylation at both the 5 and 10 min time points. To further examine the effect of this apparent Ala þ TIMP-2-mediated reduction in PLC-g activation at 5 min, we measured cytosolic Ca þ 2 levels, which are normally increased in response to PLC-g activation by VEGFR-2. 21 Figure 2c shows that VEGF-A stimulation results in a significant biphasic Ca þ 2 flux that starts at B60 s and shows a maximal response at 120 s, followed by a gradual return to baseline at 300 s. In contrast, 50 nM Ala þ TIMP-2 or TIMP-2 treatment severely attenuates the initial phase of the Ca þ 2 flux that starts a 60 s and completely abrogates the Ca þ 2 spike that occurs around 120 s after VEGF-A treatment. The calcium-chelating agent, BAPTA-AM (negative control), suppressed both phases of the intracellular Ca þ 2 increase usually observed after VEGF-A stimulation. These results are consistent with the Ala þ TIMP-2-mediated decreased association of PLC-g with VEGFR-2 showed by co-immunoprecipitation experiments (Figure 2a ), and decrease in PLC-g phosphorylation/activation. In addition, these data also support the multiple modes of PLC-g regulation and the recent observation that activation of PLC-g requires overcoming auto-inhibition by the c-terminal SH2 domain, which is regulated by the split pleckstrin homology (sPHN) domain that occurs independently of Y 783 phosphorylation. 22 Accordingly these findings may account for the apparent dissociation of PLC-g phosphorylation/activation and the suppression of Ca þ 2 cytosolic flux between 2 and 5 min.
Ala þ TIMP-2 Inhibits Phosphorylation/Activation of AKT and eNOS Phosphorylation of Y 1175 allows activation of the PI3K/AKT signaling pathway. 23 To assess the effect of Ala þ TIMP-2-mediated reduction of Y 1175 phosphorylation on downstream signaling via the PI3K/AKT pathway, we determined the level of AKT activation by assaying the phosphorylation status of serine 473 (S 473 ). 24 Ala þ TIMP-2 significantly attenuated AKT phosphorylation on S 473 at both 5 min (60% inhibition) and 10 min (40% inhibition) after VEGF-A stimulation (Figure 3a) . The Ala þ TIMP-2-mediated decrease in phosphorylation at this site was absent at the latter time point (30 min), further emphasizing the importance of suppressed AKT activation at the critical time point for activation of downstream pathways.
PLC-g-associated intracellular Ca 2 þ flux is associated with calmodulin-mediated activation of eNOS, 25 but eNOS acti- Figure 1 Ala þ TIMP-2 suppresses VEGF-A-induced maximal phosphorylation of select tyrosine residues in VEGFR-2 in hMVECs. hMVECs stimulated with VEGF-A (10 ng/ml) for indicated time periods after pretreatment in the presence or absence of Ala þ TIMP-2 (50 nM, 15 min) were subjected to western blot analysis with commercial antibodies. The western blots shown are representative of three independent experiments. Relative band intensities were measured by NIH image software and integrated densities were normalized against the VEGFR-2 loading control. Immunoblotting was performed using the antibody directed against pY 783 PLC-g and PLC-g (loading control). Band intensities were integrated using NIH Image software and normalized using total PLC-g at 0 min. Results are representative of three independent experiments. (c) Intracellular Ca 2 þ influx was measured using fura-2. hMVECs were treated with VEGF-A (10 ng/ml) in the absence or presence of Ala þ TIMP-2 (50 nM), TIMP-2 (50 nM), or BAPTA-AM (10 mM). Specific cell treatments are indicated by arrows and legend. Each tracing is the average response of B60 cells. Experiments were performed in triplicate and shown are representative tracings.
TIMP-2 modulates VEGFR-2 and PDE activity S-J Lee et al vation may also be directly mediated by AKT phosphorylation of eNOS on S 1177 in a Ca 2 þ -independent manner. 26 As we have shown earlier that TIMP-2 significantly suppresses the PLC-g-mediated cytosolic Ca þ 2 flux, we evaluated eNOS activation status by examining S 1177 phosphorylation status. VEGF-A-induced eNOS phosphorylation on S 1177 was inhibited 40% by Ala þ TIMP-2 at 10 min after stimulation ( Figure 3b ). As maximal VEGF-A-induced phosphorylation of S 1177 was observed at 10 min, these data are consistent with the suppression of maximal eNOS activation at 10 min. Collectively, these findings are consistent with suppression of maximal VEGFR-2 phosphorylation on Y 951 , and Y 1175 , in response to Ala þ TIMP-2 treatment, resulting in suppression of both the PLC-g and PI3K/AKT signaling pathways, and are consistent with the observed downregulation of eNOS activation. These results led us to analyze NO and further downstream signaling after Ala þ TIMP-2 treatment and VEGF-A stimulation of hMVECs.
TIMP-2 Inhibits VEGF-A-Induced NO Synthesis
Total NO levels were determined in VEGF-A-stimulated hMVEC in the absence or presence of TIMP-2, Ala þ TIMP-2, or the NOS inhibitor L-NAME, Figure 4 . VEGF-A evoked a twofold increase in total NO synthesis compared with basal conditions. In the presence of TIMP-2 or Ala þ TIMP-2, we observed a statistically significant (Po0.001) inhibition of VEGF-A-stimulated total NO production close to basal levels and similar to those observed with L-NAME (Po0.01), Figure  4a . TIMP-2 and Ala þ TIMP-2 both significantly reduced cytosolic NO levels close to basal levels (Po0.001), Figure 4b .
The equipotent activity of TIMP-2 and Ala þ TIMP-2 suggests that these effects were independent of MMP inhibition. These results are consistent with the reduced phosphorylation/activation of eNOS observed earlier ( Figure 3b ) and suggest that the 40% reduction in eNOS phosphorylation, combined with reduced cytosolic Ca þ 2 flux, are sufficient to reduce eNOS activity below the threshold level necessary for elevation of either total or cytosolic NO levels.
TIMP-2 Inhibits VEGF-A-Stimulated Increase in Cellular cGMP
Conformational changes resulting from NO binding to the sixth position of the heme ring of soluble guanylyl cyclase (sGC) leads to a 200-fold increase in activation of the enzyme, and subsequent increase in cytosolic cGMP levels. 27 In this study, we show that VEGF-A stimulation leads to a maximal fourfold increase in cGMP synthesis at 10 min, Figure 5a . Alternatively, in the presence of 50 nM concentrations of Ala þ TIMP-2 (or TIMP-2), the normal VEGF-Ainduced cGMP increase was suppressed to levels similar to those observed in the presence of the eNOS inhibitor L-NAME, Figure 5a . The suppression of cGMP production in the presence of Ala þ TIMP-2, TIMP-2 and L-NAME are all statistically significant (Po0.01) at the 10 min time point, which was the point of maximal cGMP response to VEGF-A. These findings are consistent with our previous observations that TIMP-2 or Ala þ TIMP-2 decreased both VEGFR-2 phosphorylation and eNOS activity. We have shown earlier that the effects of TIMP-2 on hMVEC growth and migration are sensitive to the nonspecific PTP inhibitor orthovanadate (Na 3 VO 4 ) and expression of dominant negative Shp1 (dnShp1). 11, 12, 28 Given that Okadaic acid suppresses the serine/threonine phosphatase activity of protein phosphatase 2a (PP2a) that modulates phosphorylation/activation of eNOS on S 1177 we examined whether inhibition of either PTP or PP2a activities would reverse the TIMP-mediated suppression of VEGF-A-induced cGMP synthesis through alteration of VEGFR-2 or eNOS phosphorylation. 29 To this end, we determined the effects of both Na 3 VO 4 and okadaic acid on cellular cGMP levels after VEGF-A stimulation with or without Ala þ TIMP-2 treatment. Both orthovanadate and okadaic acid slightly inhibited VEGF-A-induced cGMP synthesis in hMVECs without TIMP-2 treatment, Figure 5b . However, the addition of either orthovanadate (1 mM) or okadaic acid (100 nM) cannot reverse the essentially complete suppression of VEGF-A-induced cGMP synthesis in hMVEC after Ala þ TIMP-2 treatment, Figure 5b . These findings imply that the suppression of increased VEGF-Ainduced cGMP levels observed after Ala þ TIMP-2 treatment is not mediated solely via induction of Shp-1 or PP2a. Therefore, it is reasonable to assume that modulation of cGMP levels by Ala þ TIMP-2 occurs through additional mechanisms that are independent of the Ala þ TIMP-2mediated decrease in VEGFR-2 phosphorylation and subsequent suppression of eNOS activation. 
TIMP-2 Suppresses cGMP Production in Response to Exogenous NO Donors
To further examine this novel TIMP-2 signaling effect, we determined the ability of Ala þ TIMP-2 to inhibit cGMP synthesis initiated by exogenous NO-donors. DETA/NO or SNAP are exogenous NO donors that can directly activate soluble guanylyl cyclase (sGC) and increase cytosolic cGMP levels. 30 Treatment of hMVECs with 10 mM of DETA/NO or SNAP for 5 min resulted in a significant increase in cGMP over basal levels, Figure 6a . DETA/NO gave B5.5-fold increase, while SNAP gave a slightly lower, but still statistically significant B3.5-fold increase over basal levels. Somewhat surprisingly, Ala þ TIMP-2 (or TIMP-2) inhibited DETA/ NO-or SNAP-induced cGMP synthesis in hMVECs in a statistically significant manner (Po0.001) comparable to levels observed with the selective guanylyl cyclase inhibitor ODQ (Figure 6a) .
Previous studies show that NO effects on endothelial cell proliferation and migration are concentration dependent. DETA/NO at concentrations below 100 mM stimulate TIMP-2 modulates VEGFR-2 and PDE activity S-J Lee et al proliferation and migration of endothelial cells, but inhibit these cellular responses at higher concentrations. 30 Similarly, treatment of hMVECs with 10 or 100 mM of DETA/NO or SNAP results in a two-to threefold increase in cell proliferation compared with basal levels. In this study, we show that Ala þ TIMP-2 suppresses hMVEC proliferation after either 10 or 100 mmole/l of DETA/NO or SNAP in a statistically significant manner (Po0.001), Figure 6b . Although treatment with 10 mmole/l DETA/NO showed a twofold increase in spontaneous cell migration of hMVECs compared with basal migration, addition of Ala þ TIMP-2 showed statistically significant inhibition of NO-stimulated cell migration at all concentrations tested, Figure 6c . In fact, Ala þ TIMP-2 inhibited spontaneous hMVEC migration at 0 mM DETA/NO, consistent with out previous findings. 28 These studies show that Ala þ TIMP-2 (or TIMP-2) directly downregulates exogenous NO donor-mediated increase in cGMP, as well as downstream suppression of cGMP-mediated increased hMVEC proliferation (DETA/NO and SNAP, Figure 6b ) and migration DETA/NO, Figure 6c ). It is possible that Ala þ TIMP-2 (and TIMP-2) modulate cGMP levels by either suppressing sGC activity or enhancing phosphodiesterase (PDE) activity. Indeed, we showed that VEGF-A, Ala þ TIMP-2 (and TIMP-2) suppress exogenous NO-induced hMVEC mitogenesis to near basal levels (Figure 6b ), and our earlier data show that Ala þ TIMP-2 suppresses eNOS activation and elevation of cytosolic cGMP levels. Given that NO directly activates sGC, this enzyme may be a target of the Ala þ TIMP-2 anti-angiogenic signal. In contrast, an alternative mechanism for the Ala þ TIMP-2 suppression of cGMP levels may involve activation of cGMP PDE activity. In the latter case, if PDE activation significantly contributes to the mechanism of Ala þ TIMP-2 suppression of increased cGMP, inhibition of PDE activity should reverse these effects.
To evaluate this hypothesis, we measured cGMP levels in the presence of an exogenous NO donor (DETA/NO) with or without Ala þ TIMP-2 after pretreatment with a non-selective phosphodiesterase inhibitor IBMX, Table 1 . Pretreatment of hMVECs with IBMX, led to a 1.4-fold increase in basal level of cGMP. The cells treated with NO donors in the presence of Ala þ TIMP-2 caused a 7.8-fold increase in cGMP levels while the cells treated with NO donors resulted in a 1.8-fold increase in cGMP compared with cells not treated with IBMX. Two-way ANOVA test of TIMP-2 modulates VEGFR-2 and PDE activity S-J Lee et al these data show that both the effects of the Ala þ TIMP-2 treatment and the IBMX are highly significant (Po0.001) when compared with the control and DETA/NO alone groups. These results clearly suggest that the TIMP-2mediated signaling is capable of inducing activity of a PDE isoform. However, the identification of the specific PDE is beyond the scope of the present study.
DISCUSSION
The anti-mitogenic effects of TIMP-2 in both neoplastic and endothelial cells are independent of the ability to inhibit MMP activity. 9, 11, 31 Furthermore, the anti-mitogenic activity of TIMP-2 and the Ala þ TIMP-2 analog are mediated by a mechanism of heterologous receptor inactivation involving the binding of Ala þ TIMP-2 (or TIMP-2) to the a3b1 integrin receptor enhancing PTP activity resulting in reduced activation of the cognate RTKs. 11 Murine genetic models, siRNA knockdown and biochemical experiments have been used to show the requirement for a3 and b1 integrin subunits, and definitively identified the PTP activity as the PTP Shp-1. 11, 12, 31 Subsequent work demonstrated that Ala þ TIMP-2 could disrupt FGF-2-mediated activation of mitogen-activated protein kinase pathway (MAPK) through an integrin a3 and Shp-1-dependent mechanism. 10 In this report, we have extended these studies to show that Ala þ TIMP-2 suppresses maximal phosphorylation of specific tyrosine residues in the cytoplasmic domain of VEGFR-2, that diminished receptor activation is manifest in disruption of downstream signaling as evidenced by the abatement of PLC-g activation and associated cytosolic Ca þ 2 flux, as well as curtailment of PI3K/AKT activation. We also show that Ala þ TIMP-2 abates the maximal activation of eNOS and increased NO levels observed after VEGF-A stimulation, as well as the subsequent elevation of cGMP levels, associated with an enhanced mitogenesis and migration of endothelial cells. Our study also shows that Ala þ TIMP-2 regulation of cGMP levels can occur independently of PTP activity via regulation of PDE activity. Although we do not analyze the precise mechanism of PDE activation, previous work from our laboratory has implicated cyclic nucleotides in TIMP-2-mediated cell growth regulation, 32 and recent work has confirmed TIMP-2 mediated elevation of cAMP levels (Seo and Stetler-Stevenson, unpublished) consistent with the differential regulation of endothelial barrier function by PDE isoforms. 33 Ala þ TIMP-2 reduced phosphorylation of selective tyrosine residues on the cytoplasmic domain of VEGFR-2. Ala þ TIMP-2 suppressed maximal phosphorylation at three tyrosine residues, Y 951 , Y 996 , and Y 1175 . Y 951 and Y 996 are located in the tyrosine kinase insert domain of VEGFR-2. Y 951 phosphorylation results in enhanced association of this receptor with the adapter molecule VRAP/TSAd, and increases endothelial cell migration and proliferation via both PLC-g and PI3K. 7, 34 Ala þ TIMP-2 also reduced phosphorylation of Y 1175 , which is associated with the direct binding and activation of PLC-g, as well as activation of PI3K downstream signaling pathways, both resulting in enhanced endothelial cell migration and proliferation via the MAPK pathway. 21 Both Y 951 and Y 1175 of VEGFR-2 are implicated in VEGFinduced activation of eNOS, but the role of VEGFR-2 Y 996 has not been definitively determined. The VEGFR-2 mutant Y 951 F suppresses NO release through inhibition of phosphorylation of eNOS at S 1177 . 35 VEGFR-2 Y 1175 mediates AKT activation, also implicated in phosphorylation of eNOS on S 1177 . 23 In addition, PLC-g activation through phosphorylation of Y 1175 binding generates diacylglycerol and elevates intracellular Ca þ 2 , which as noted earlier is associated with calmodulinmediated activation of eNOS. 25 Therefore, we speculate that Ala þ TIMP-2 combined suppression of both these mechanisms cooperates to inhibit NO production. In summary, Ala þ TIMP-2 suppression of maximal VEGFR-2 phosphorylation on Y 951 and Y 1175 effectively eliminated all of the downstream signaling effects noted above as shown either by reduced effector activity (PLC-g, PI3K, AKT, or eNOS activity) or decreased second messenger levels (Ca þ 2 levels, NO levels, and cGMP levels), resulting in suppression of hMVEC proliferation and migration.
We have shown earlier that Ala þ TIMP-2 reduced phosphoryltion of VEGFR-2, EGFR, and FGFR-1 through an increased association of Shp-1 with these receptors. 10, 11, 31 This led us to examine the phosphorylation of VEGFR-2 cytoplasmic tail after Ala þ TIMP-2 treatment. We speculate that the specificity of this heterologous receptor inactivation mechanism of Ala þ TIMP-2 inhibition of RTK phosphorylation is mediated by creation of receptor SH2-domains after activation of the receptor kinase domain. This hypothesis would explain the observation that phosphorylation of Y 1059 on VEGFR-2 after Ala þ TIMP-2 is unchanged, as this site is central for kinase activity. This finding also contrasts with a recent report describing autoregulation of VEGFR-2 phosphorylation by Shp-1 after VEGF-A binding in which Y 1059 decreases, but Y 951 is not effected. 36 This difference suggests that heterologous vs autologous downregulation of VEGFR-2 are distinct, and one consequence is the alteration of cell motility probably regulated by Y 951 . In summary our present findings expand on previous reports showing that the anti-angiogenic effects of TIMP-2 involve as Shp-1-dependent mechanism of heterologous receptor inactivation. We show that Ala þ TIMP-2 selectively downregulates maximal phosphorylation of VEGFR-2 on Y 951 , Y 996 , and Y 1175 , with concomitant suppression of PI3K and PLC-g signaling, resulting in abrogation of VEGF-Astimulated hMVEC proliferation and migration. In addition, we observed that Ala þ TIMP-2 enhanced activity of an IBMX-sensitive PDE that suppresses the cGMP increase after treatment with exogenous NO donors. Moreover, our results support the development of TIMP-2 as a novel, endogenous anti-angiogenic therapy that may complement those therapies already in clinical use or in preclinical trials.
